ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 892,61
0,70%
Dow Jones
44 492,56
0,76%
DAX
21 411,53
0,72%
Brent Oil
77,555
-1,00%
Bitcoin
103 948,06
0,30%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) Actualités

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRLD
DateHeureSourceTitreSymboleSociété
07/01/202522h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202413h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202413h30GlobeNewswire Inc.Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesNASDAQ:PRLDPrelude Therapeutics Inc
27/11/202413h30GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitNASDAQ:PRLDPrelude Therapeutics Inc
06/11/202422h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
06/11/202422h05GlobeNewswire Inc.Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
24/10/202413h30GlobeNewswire Inc.Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR SymposiumNASDAQ:PRLDPrelude Therapeutics Inc
09/10/202413h30GlobeNewswire Inc.Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumNASDAQ:PRLDPrelude Therapeutics Inc
13/09/202416h00GlobeNewswire Inc.Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialNASDAQ:PRLDPrelude Therapeutics Inc
09/09/202413h30GlobeNewswire Inc.Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/08/202413h01GlobeNewswire Inc.Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
09/07/202413h30GlobeNewswire Inc.Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated CancersNASDAQ:PRLDPrelude Therapeutics Inc
11/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
03/06/202413h01GlobeNewswire Inc.Prelude Therapeutics to Participate in Upcoming Healthcare ConferencesNASDAQ:PRLDPrelude Therapeutics Inc
30/05/202422h29Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PRLDPrelude Therapeutics Inc
16/05/202422h09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/05/202413h01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202422h24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202422h35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202422h45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202423h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422h05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
11/12/202315h34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202318h30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
29/08/202314h30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD

Dernières Valeurs Consultées

EU
RI
Pernod Ricard
EU
AF
Air FranceKLM
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
MRK
Merck
EU
AI
Air Liquide
EU
HO
Thales
EU
EN
Bouygues
EU
CAP
Capgemini
NASDAQ
GOOGL
Alphabet
EU
BNP
BNP Paribas
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés